Zanubrutinib Shows Clinical Benefits in Waldenstrom Macroglobulinemia

[Anonymous]

ONCOLOGIST, 2020; 25 (): S16

Abstract

In the head-to-head phase III ASPEN trial, zanubrutinib showed clinically meaningful improvements in safety and tolerability versus ibrutinib, with co......

Full Text Link